Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Insulin degludec/liraglutide (IDegLira) is a novel combination of insulin degludec (IDeg) and liraglutide. This trial investigated the contribution of the liraglutide component of IDegLira versus IDeg alone on efficacy and safety in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: In a 26-week, double-blind trial, patients with type 2 diabetes (A1C 7.5–10.0% [58–86 mmol/mol]) on basal insulin (20–40 units) and metformin with or without sulfonylurea/glinides were randomized (1:1) to once-daily IDegLira + metformin or IDeg + metformin with titration aiming for fasting plasma glucose between 4 and 5 mmol/L. Maximum allowed doses were 50 dose steps (equal to 50 units IDeg plus 1.8 mg liraglutide) and 50 units for IDeg. The primary end point was change in A1C from baseline. RESULTS: A total of 413 patients were randomized (mean A1C 8.8% [73 mmol/mol]; BMI 33.7 kg/m2). IDeg dose, alone or as part of IDegLira, was equivalent (45 units). A1C decreased by 1.9% (21 mmol/mol) with IDegLira and by 0.9% (10 mmol/mol) with IDeg (estimated treatment difference −1.1% [95% CI −1.3, −0.8], −12 mmol/mol [95% CI −14, −9; P < 0.0001). Mean weight reduction with IDegLira was 2.7 kg vs. no weight change with IDeg, P < 0.0001. Hypoglycemia incidence was comparable (24% for IDegLira vs. 25% for IDeg). Overall adverse events were similar, and incidence of nausea was low in both groups (IDegLira 6.5% vs. IDeg 3.5%). CONCLUSIONS: IDegLira achieved glycemic control superior to that of IDeg at equivalent insulin doses without higher risk of hypoglycemia and with the benefit of weight loss. These findings establish the efficacy and safety of IDegLira and the distinct contribution of the liraglutide component.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In studies of people with type 2 diabetes inadequately controlled on basal insulin or GLP-1 RA, switching to a fi xedratio combination of basal insulin and GLP-1 RA demonstrated signi fi cant improvements in blood glucose levels and achievement of glycemic goals with fewer hypoglycemic events than with basal insulin alone (216 -220).”
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citationManagement of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Self-citationBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Self-citationWorld Medical Association Declaration of Helsinki
(2003) · Psychopharmacology · doi:10.1002/047086947x.oth1 · Cited by 1,332
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Inzucchi, S., Bergenstal, R., Buse, J., Diamant, M., Ferrannini, E., Nauck, M., Peters, A., Tsapas, A., Wender, R., & Matthews, D. (2013) · Diabetes Care · doi:10.2337/dc13-er02 · Cited by 805
Self-citationPeyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655
Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565
Self-citationBuse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506 · cited 1×
“IDegLira combines the complementary effects of IDeg and liraglutide on glycemic control (10,11,12).”
BackgroundSelf-citationGough, S. C. L., Bode, B., Woo, V., Rodbard, H. W., Linjawi, S., Poulsen, P., Damgaard, L. H., & Buse, J. B. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70174-3 · Cited by 366 · cited 1×
“IDeg in patients with type 2 diabetes inadequately controlled on metformin with or without pioglitazone supports the benefits of IDegLira compared with IDeg as well as liraglutide (21).”
BackgroundSelf-citation
Cited by
Items 201–265 of 265
United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes
Rendell, M. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s132581 · Cited by 3
Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c.
Chung, J. W., Hartzler, M. L., Smith, A. A., Hatton, J., & Kelley, K. W. (2018) · Europe PMC (PubMed Central) · Cited by 5
Blonde, L., & Fonseca, V. A. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0293 · Cited by 2
Janež, A., Örsy, P., Stachlewska, K., Salvesen‐Sykes, K., Billings, L. K., & Philis‐Tsimikas, A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13944 · Cited by 7
“This was a post hoc analysis of the DUAL II (NCT01392573)(14) and DUAL IX (NCT02773368)(20) trials, which have been described in full in their respective primary reports.(14,20) Both trials were phase III, randomized (1:1), multinational, multicentre, treat-to-target trials, with a 26-week treatment duration.”
BackgroundMethodResultInsulin degludec/liraglutide in type 2 diabetes: a profile of its use
Heo, Y. (2020) · Drugs & Therapy Perspectives · doi:10.1007/s40267-020-00731-z · Cited by 3
“…and in insulin‑experienced patients… In DUAL-II [13], -”
BackgroundResultInfluentialIDeglira vs insulin degludec for type 2 diabetes: a systematic review and meta-analysis
Liu, Y., Li, X., Yang, J., Qie, S., Wang, X., Wang, X., & Zheng, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1643386 · Cited by 1
Wang, S., Sun, B., Zhu, D., Shen, Z., Zhong, X., & Chen, L. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01852-w · Cited by 1
Zhang, J., Wang, W., Man, F., Wang, X., Pan, Q., & Guo, L. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100497 · Cited by 1
“The contribution of liraglutide within the fixed-ratio combination has been evaluated in a component study [14].”
Insulin degludec + liraglutide: a complementary combination
Stinkens, K., Peene, B., & Mathieu, C. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1217328 · Cited by 3
“Approval was mainly based on two pivotal phase III trials, DUAL I [27] and DUAL II [28] (Table 1).”
MethodPharmacodynamic Evaluation: Diabetic Methodologies
SANDOW, J. (2020) · Springer eBooks · doi:10.1007/978-3-319-68864-0_33 · Cited by 1
A glorious past, dynamic present and a promising future: Insulin at 100
Sharma, J. K., Sharma, D., & Gupta, A. S. (2022) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/14782715221088981 · Cited by 1
Lamos, E. M., & Davis, S. N. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1216974 · Cited by 1
“Select reports adverse events in DUAL I and DUAL II [10,11].”
BackgroundMontanya, E. (2016) · Springer eBooks · doi:10.1007/978-3-319-08982-9_6 · Cited by 1
Crasto, W., Jarvis, J., & Davies, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-10939-8_3 · Cited by 1
Efficacy, safety and clinical use of newer basal insulins analogs
Neto, A. M., & Ferrari, M. T. M. (2018) · Endocrinology&Metabolism International Journal · doi:10.15406/emij.2018.06.00178 · Cited by 2
Future Drug Treatments for Type 1 Diabetes
Sherr, J. L., Cengiz, E., Name, M. A. V., WEINZIMER, S. A., & Tamborlane, W. V. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch66 · Cited by 1
Eggert, S., Zimmermann, E., & Begtrup, K. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1444882 · Cited by 1
“OADs [5,6], and some on maximum tolerated dose of a GLP-1 RA [7].”
BackgroundMethodInsulin Management in Type 2 Diabetes
Crasto, W., Jarvis, J., & Davies, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-10939-8_4 · Cited by 1
Obesity and diabetes: pointing the way
Greener, M. (2015) · Practical Diabetes · doi:10.1002/pdi.1957
Seewoodhary, J., & Wong, S. P. Y. (2015) · Practical Diabetes · doi:10.1002/pdi.1932
New treatments for type 2 diabetes: are we any closer to reducing iatrogenic hypoglycaemia?
Seewoodhary, J., Wong, S. P. Y., & Ekanayake, K. P. (2015) · Practical Diabetes · doi:10.1002/pdi.1977
The place of IDegLira in the management of patients with Type 2 diabetes
Lansdown, A., Bain, S. C., & Chudleigh, R. A. (2015) · Diabetes Management · doi:10.2217/dmt.15.29
Treatment: Concepts and new developments
Bloomgarden, Z. T., & Drexler, A. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12381
Combination therapy of GLP-1 analogues and insulin: do the benefits outweigh the costs?
Versmissen, J. (2014) · PubMed
Antidiabetic drugs of interest
Kvapil, M. (2016) · Interní medicína pro praxi · doi:10.36290/int.2016.036
Slower Titration of Liraglutide Achieves better Tolerability in some Patients
Grajower, M. M. (2017) · AACE Clinical Case Reports · doi:10.4158/ep171826.cr
“Liraglutide has been studied as a combination injection together with insulin degludec (2).”
BackgroundZeitnahe Intensivierung prognostisch wichtigt
Fath, R. (2016) · Info Diabetologie · doi:10.1007/s15034-016-0813-4
The role of emerging insulin and regimens in overcoming insulin treatment resistance
Barag, S., Meshefedjian, T., & Diep, K. (2017) · Integrative Obesity and Diabetes · doi:10.15761/iod.1000194
“Studies conducted regarding dual treatment with degludec and liraglutide have demonstrated efficacy in lowering hemoglobin A1c, reducing weight gain, while demonstrating similar adverse events to insulin glargine [14].”
BackgroundA practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetes
Goldenberg, R., Assimakopoulos, P., Gilbert, J. D., Gottesman, I. S., & Yale, J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13337
“2 kg), with similar or lower rates of hypoglycaemia in the FRC groups.(73,74) A study comparing”
BackgroundMethodPogorelova, A. S. (2018) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-12-118-126
Peptide Drug Design for Diabetes and Related Metabolic Diseases
Kaarsholm, N. C. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_13
Pharmacodynamic Evaluation: Diabetic Methodologies
SANDOW, J. (2019) · Springer eBooks · doi:10.1007/978-3-319-56637-5_33-1
Czarnowski, K., Silver, C., Wood, B., UNDERWOOD, P. C., & Patel, D. K. (2019) · Europe PMC (PubMed Central)
New Medications for the Treatment of Diabetes
Garg, S. K., Polsky, S., & Shah, V. N. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.1514
When and how to Use Prandial Insulin with Ultralong-Acting Basal Insulin in T2Dm
Umpierrez, G. E. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)42964-7
When and how to Use Ultralong-Acting Basal Insulin in T2Dm
Garber, A. J. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)42963-5
When and how to Use A Glp-1 ra With Long- or Ultralong-Acting Basal Insulin in T2Dm
Bode, B. W. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)42965-9
Garber, A. J. (2016) · Endocrine Practice · doi:10.4158/1934-2403-22.s5.1
Liu, H., Luo, B., Chen, X., Ingwersen, S. H., Jia, T., Jacobsen, L. V., & Hu, P. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13716 · Cited by 1
Incretin‐Based Therapy for the Management of Type 2 Diabetes
Gonzales, K., & Vella, A. V. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch12
Суть аудита - объективный анализ и экспертиза
Катышева, И., & Малкин, А. М. (2001) · Директор школы
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_20 · Cited by 1
Type 2 diabetes: glycaemic control
FRCP, D. L. M. (2017) · Wiley eBooks · doi:10.1002/9781119052210.ch10
Manuscripts Reviewed for the 2014 Yearbook
(2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.1515
de Medeiros, M. S., Gallani, J. D. A., & Swiech, J. N. D. (2022) · Research Society and Development · doi:10.33448/rsd-v11i15.36858
Session Two: Changing the Type 2 Diabetes Mellitus Management Paradigm with Fixed-Ratio Combinations
Michel, L. (2017) · EMJ Diabetes · doi:10.33590/emjdiabet/10310975
Garnica-Cuéllar, J. C., Morales-Villegas, E., López-Forero, C. A., Monroy-Cruz, B., Pariti, B., Deshwal, S., Sekharan, M., Osorio-Hernández, M., & García-Appendini, I. C. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-023-00421-2
“sources for the ITC: IDegLira trials—DUAL II [23] and DUAL V [18]; IGlarLixi trials—LixiLan-L [24].”
MethodDelphi, B. (2023) · The Journal of AMD · doi:10.36171/jamd23.26.4.3
Bai, L., Liu, D., Su, N., Zhang, L., & Yang, Z. (2025) · Current Diabetes Reviews · doi:10.2174/0115733998359708250822102217
Hassanein, M. M., Alessa, T., Hafidh, K., Alzubaidi, L. M. Y., Jallo, M. K. I., Slail, F. Y. A., Elbadawi, H., & Malik, R. A. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01824-6
Wei, R., Wang, W., Huang, X., Qiao, J., Huang, J., Xing, C., Pan, Q., & Guo, L. (2024) · Figshare · doi:10.6084/m9.figshare.26611550
Wei, R., Wang, W., Huang, X., Qiao, J., Huang, J., Xing, C., Pan, Q., & Guo, L. (2024) · Figshare · doi:10.6084/m9.figshare.26611553
Wei, R., Wang, W., Huang, X., Qiao, J., Huang, J., Xing, C., Pan, Q., & Guo, L. (2024) · Figshare · doi:10.6084/m9.figshare.26611547
Wei, R., Wang, W., Huang, X., Qiao, J., Huang, J., Xing, C., Pan, Q., & Guo, L. (2024) · Figshare · doi:10.6084/m9.figshare.26611544
Szépkúti, S., Bandur, S., Kovács, G., Ferenci, T., Svébis, M. M., Turbucz, P., & Tabák, Á. G. (2022) · Figshare · doi:10.6084/m9.figshare.21117530
Wei, R., Wang, W., Huang, X., Qiao, J., Huang, J., Xing, C., Pan, Q., & Guo, L. (2024) · Figshare · doi:10.6084/m9.figshare.26611541
インスリン療法で血糖コントロールが不十分な成人2型糖尿病患者に対するインクレチン関連薬追加療法の臨床試験間の異質性の解析とその応用
克也, 澁., & 澁木, 克. (2022) · Institutional Repositories DataBase (IRDB) · doi:10.20604/00003779
Saab, C., Mansour, A. A., Rahmah, A. M., Al-Attar, D. M. R. A., Alrubaye, H. F., Alidrisi, H. A., Nwayyir, H. A., Khudhair, M. S., Ahmed, M. J., AL-Ibrahimi, S. M., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01861-9
“…GLP‑1 RAs (as separate injec‑ tions or FRCs) due to improved glycemic con‑ trol with particular benefits for both fasting and postprandial glucose control [43–47] and their safety profile while minimizing gastrointestinal side effects as compared to GLP1‑RAs alone due to gradual titration [48, 49].”
Mohammadi, D., Sadeghirad, B., Rasouli, M. A., Saed, L., Baradaran, H. R., & Moradi, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02226-9
Strojek, K., Liebl, A., Mumbaikar, N. N., Søgaard, S. B., Watt, S. K., & Philis‐Tsimikas, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71049
(2026) · ADA Clinical Compendia · doi:10.2337/db20261-33
Stüdemann, S., Gollasch, M., & Engeli, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1786211
Kamrul-Hasan, A. B. M., Mondal, S., Nagendra, L., Khalil, I., Dutta, D., & Pappachan, J. M. (2026) · Endocrine · doi:10.1007/s12020-026-04857-4
“…of the respective BI–GLP1RA FRCs in the control arms [ 27–29, 48, 49, 53 ]; 13 used the BI component of the respective BI–GLP1RA FRCs [ 23, 30–32, 35, 37–39, 41, 43, 44, 46, 47, 52 ]; three used BB insulins [ 25, 26, 36 ]; two used biphasic insulins [ 50, 51 ]; four used GLP1RAs [ 24, 33,…”
Metadata
- Authors
- Buse, J. B., Vilsbøll, T., Thurman, J., Blevins, T. C., Langbakke, I. H., Bøttcher, S. G., & Rodbard, H. W.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- University of Copenhagen (DK)
- SSM Health Care (US)
- Texas Diabetes & Endocrinology (US)
- Novo Nordisk (Denmark) (DK)
- Endocrine and Metabolic Consultants, Clinical Research, Rockville, MD
- Corresponding author
- Buse, John B.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-10-10
- Volume
- 37
- Issue
- 11
- Pages
- 2926-2933
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2126862523
- Cited by
- 259
- References
- 27
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 10 · 2023: 11 · 2022: 14 · 2021: 14 · 2020: 16 · 2019: 30 · 2018: 39 · 2017: 41 · 2016: 30 · 2015: 26 · 2014: 4
- FWCI
- 26.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk Fonden (NNF12OC1015904)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin degludec, liraglutide, IDegLira, type 2 diabetes, glycemic control, HbA1c, weight loss, hypoglycemia, basal insulin, metformin, GLP-1 receptor agonists, nausea, fixed-dose combination
- MeSH terms
- Liraglutide, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Metformin, Middle Aged, Sulfonylurea Compounds, Weight Loss, Treatment Outcome, Insulin, Long-Acting, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.